C4 Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
C4 Therapeutics, Inc. (CCCC) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $471.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-11
- C4 Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $3.99M, a 536.84% increase year-over-year.
- C4 Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$3.52M.
- C4 Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $2.07M, a 47.95% decline year-over-year.
- C4 Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$2.02M, a 148.30% decline year-over-year.
- C4 Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$6.05M.
- C4 Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$1.27M, a 196.28% decline from fiscal 2023.
- C4 Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $1.32M, a 74.11% decline from fiscal 2022.
- C4 Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $5.08M, a 16.13% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $3.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $471.00K 10-Q · filed 2026-08-11 | $2.54M derived: sum of 3 quarters · filed 2026-08-11 | $525.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$3.52M 10-Q · filed 2026-05-12 | -$1.45M derived: sum of 2 quarters · filed 2026-05-12 | -$3.47M derived: sum of 3 quarters · filed 2026-05-12 | -$2.84M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $54.00K derived: sum of 2 quarters · filed 2026-02-26 | $681.00K derived: sum of 3 quarters · filed 2026-08-11 | -$6.05M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.39M derived: sum of 2 quarters · filed 2026-08-11 | -$8.12M 10-Q · filed 2025-11-06 | -$4.14M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $627.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$6.10M 10-Q · filed 2026-08-11 | -$2.13M derived: sum of 3 quarters · filed 2026-08-11 | $2.04M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$6.73M 10-Q · filed 2026-05-12 | -$2.75M derived: sum of 2 quarters · filed 2026-05-12 | $1.42M derived: sum of 3 quarters · filed 2026-05-12 | -$334.00K derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $3.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.15M derived: sum of 2 quarters · filed 2026-02-26 | $6.40M derived: sum of 3 quarters · filed 2026-02-26 | -$1.27M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $4.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.42M derived: sum of 2 quarters · filed 2025-11-06 | -$5.24M 10-Q · filed 2025-11-06 | -$60.00K derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | -$1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$9.41M 10-Q · filed 2025-08-07 | -$4.23M derived: sum of 3 quarters · filed 2025-08-07 | -$4.96M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$7.66M 10-Q · filed 2025-05-07 | -$2.48M derived: sum of 2 quarters · filed 2025-05-07 | -$3.21M derived: sum of 3 quarters · filed 2025-05-07 | -$2.68M derived: sum of 4 quarters · filed 2025-05-07 | |
| 2023-12-31 | $5.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.45M derived: sum of 2 quarters · filed 2025-02-27 | $4.99M derived: sum of 3 quarters · filed 2025-02-27 | $1.32M 10-K · filed 2025-02-27 | |
| 2023-09-30 | -$733.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$196.00K derived: sum of 2 quarters · filed 2024-10-31 | -$3.87M 10-Q · filed 2024-10-31 | -$1.17M derived: sum of 4 quarters · filed 2024-10-31 | |
| 2023-06-30 | $537.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$3.13M 10-Q · filed 2024-08-01 | -$441.00K derived: sum of 3 quarters · filed 2024-08-01 | $2.04M derived: sum of 4 quarters · filed 2024-08-01 | |
| 2023-03-31 | -$3.67M 10-Q · filed 2024-05-08 | -$978.00K derived: sum of 2 quarters · filed 2024-05-08 | $1.50M derived: sum of 3 quarters · filed 2024-05-08 | $5.18M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | $2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $5.17M derived: sum of 2 quarters · filed 2024-02-22 | $8.85M derived: sum of 3 quarters · filed 2024-02-22 | $5.08M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $2.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $6.16M derived: sum of 2 quarters · filed 2023-11-01 | $2.39M 10-Q · filed 2023-11-01 | $4.53M derived: sum of 4 quarters · filed 2023-11-01 | |
| 2022-06-30 | $3.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$87.00K 10-Q · filed 2023-08-08 | $2.05M derived: sum of 3 quarters · filed 2023-08-08 | $3.97M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$3.77M 10-Q · filed 2023-05-04 | -$1.63M derived: sum of 2 quarters · filed 2023-05-04 | $295.00K derived: sum of 3 quarters · filed 2023-05-04 | $4.28M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $4.06M derived: sum of 2 quarters · filed 2023-02-23 | $8.04M derived: sum of 3 quarters · filed 2023-02-23 | $4.38M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $1.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $5.91M derived: sum of 2 quarters · filed 2022-11-03 | $2.24M 10-Q · filed 2022-11-03 | $1.64M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | $3.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $316.00K 10-Q · filed 2022-08-04 | -$282.00K derived: sum of 3 quarters · filed 2022-08-04 | $3.50M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$3.67M 10-Q · filed 2022-05-05 | -$4.26M derived: sum of 2 quarters · filed 2022-05-05 | -$480.00K derived: sum of 3 quarters · filed 2022-05-05 | $190.00K derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | -$598.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $3.19M derived: sum of 2 quarters · filed 2022-02-24 | $3.86M derived: sum of 3 quarters · filed 2022-02-24 | $2.56M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $3.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $4.45M derived: sum of 2 quarters · filed 2021-11-10 | $3.16M 10-Q · filed 2021-11-10 | $3.16M 10-Q · filed 2020-11-12 | $5.15M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $670.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$628.00K 10-Q · filed 2021-08-11 | $1.36M derived: sum of 3 quarters · filed 2022-02-24 | ||
| 2020-03-31 | -$1.30M 10-Q · filed 2021-05-13 | $692.00K derived: sum of 2 quarters · filed 2022-02-24 | |||
| 2019-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $3.72M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $1.73M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |